Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors

References

• Hoos A. Development of immuno-oncology drugs – from CTLA4 to PD1 to the next generations. Nat Rev Drug Discovery. 2016;15:235–247. doi:10.1038/nrd.2015.35.
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA. CTLA-4 can function as a negative regulator of T-cell activation. Immunity. 1994;1:405–413. doi:10.1016/1074-7613(94)90071-X. PMID:7882171.
   PubMed Web of Science ®Google Scholar
• Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543–9553. doi:10.1128/MCB.25.21.9543-9553.2005. PMID:16227604.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi:10.1038/nrc3239. PMID:22437870.
   PubMed Web of Science ®Google Scholar
• Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3:611–618 doi:10.1038/ni0702-611. PMID:12087419.
   PubMed Web of Science ®Google Scholar
• Walker LSK. Treg and CTLA-4: Two intertwining pathways to immune tolerance. J Autoimmunity. 2013;45:49–57. doi:10.1016/j.jaut.2013.06.006.
   PubMed Web of Science ®Google Scholar
• Tai XG, et al. Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood. 2012;119:5155–5163. doi:10.1182/blood-2011-11-388918. PMID:22403258.
   PubMed Web of Science ®Google Scholar
• Pusztai L, Karn T, Safonov A, Abu-Khalaf MM, Bianchini G. New strategies in breast cancer: Immunotherapy. Clin Cancer Res. 2016;22:2105–2110. doi:10.1158/1078-0432.CCR-15-1315.
   PubMedGoogle Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Eng J Med. 2010;363:711–723. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Poole RM. Pembrolizumab: First global approval. Drugs. 2014;74:1973–1981. doi:10.1007/s40265-014-0314-5. PMID:25331768.
   PubMed Web of Science ®Google Scholar
• Gunturi A, McDermott DF. Nivolumab for the treatment of cancer. Exp Opin Invest Drugs. 2015;24:253–260. doi:10.1517/13543784.2015.991819.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–1982. doi:10.1200/JCO.2014.59.4358.
   PubMed Web of Science ®Google Scholar
• Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 2016;6:827–837. doi:10.1158/2159-8290.CD-15-1545. PMID:27301722.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348:69–74. doi:10.1126/science.aaa4971. PMID:25838375.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, Lee W, Yuan J, Wong P, Ho TS, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–128. doi:10.1126/science.aaa1348. PMID:25765070.
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart M, Emancipator K, Gonzalez EJ, et al. Abstract S1-09: A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. Cancer Res. 2015;75:S1–09. doi:10.1158/1538-7445.SABCS14-S1-09.
   Web of Science ®Google Scholar
• Emens LA, Braiteh FS, Cassier P, Delord J, Eder JP, Fasso M, Xiao Y, Wang Y, Molinero L, Chen DS, et al. Inhibition of PD-L1 by MPDL3280 A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Cancer Res. 2015;75:2859. doi:10.1158/1538-7445.AM2015-2859.
   Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460–7 doi:10.1200/JCO.2015.64.8931. PMID:27138582.
   PubMed Web of Science ®Google Scholar
• Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. J Clin Oncol. 2017;35:1008–1008
   Web of Science ®Google Scholar
• Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, et al. Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B. J Clin Oncol. 2017;35:1088–1088.
   Google Scholar
• West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13:R126. doi:10.1186/bcr3072. PMID:22151962
   PubMed Web of Science ®Google Scholar
• Hornychova H, Melichar B, Tomsova M, Mergancova J, Urminska H, Ryska A. Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast Carcinoma. Cancer Invest. 2008;26:1024–1031. doi:10.1080/07357900802098165. PMID:19093260.
   PubMed Web of Science ®Google Scholar
• Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–66. doi:10.1200/jco.2013.55.0491.
   PubMed Web of Science ®Google Scholar
• Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology. 2015;4:e985930. doi:10.4161/2162402X.2014.985930. PMID:26405612.
   PubMed Web of Science ®Google Scholar
• Miyashita M, Sasano H, Tamaki K, Hirakawa H, Takahashi Y, Nakagawa S, Watanabe G, Tada H, Suzuki A, Ohuchi N, et al. Prognostic significance of tumor-infiltrating CD8(+) and FOXP3(+) lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 2015;17:13. doi:10.1186/s13058-015-0632-x. PMID:25633049.
   PubMed Web of Science ®Google Scholar
• Denkert, C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, et al. Tumor-infiltrating Lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:983–91. doi:10.1200/JCO.2014.58.1967. PMID:25534375.
   PubMed Web of Science ®Google Scholar
• Stagg J, Allard B. Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects. Therapeutic Adv Medical Oncol. 2013;5:169–181. doi:10.1177/1758834012475152.
   PubMed Web of Science ®Google Scholar
• Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology. 2017;6:e1253654. doi:10.1080/2162402X.2016.1253654. PMID:28344865.
   PubMed Web of Science ®Google Scholar
• Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, Diaz LA, Jr, Papadopoulos N, Kinzler KW, Vogelstein B, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A. 2014;111:11774–11779. doi:10.1073/pnas.1410626111. PMID:25071169.
   PubMed Web of Science ®Google Scholar
• Gao L, et al. Enhanced anti-tumor efficacy through a combination of integrin alpha v beta 6-targeted photodynamic therapy and immune checkpoint inhibition. Theranostics. 2016;6:627–637. doi:10.7150/thno.14792. PMID:27022411.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hodi FS, Kaufman HL, Wigginton JM, Wolchok JD. Combination immunotherapy: a road map. J Immunotherapy Cancer. 2017;5:16. doi:10.1186/s40425-017-0218-5.
   PubMed Web of Science ®Google Scholar
• Dunham LJ, Stewart HL. A survey of transplantable and transmissible animal tumors. J Natl Cancer Inst. 1953;13:1299–1377. PMID:13035452.
   PubMedGoogle Scholar
• Johnstone CN, Smith YE, Cao Y, Burrows AD, Cross RSN, Ling X, Redvers RP, Doherty JP, Eckhardt BL, Natoli AL, et al. Functional and molecular characterisation of EO771.LMB tumours, a new C57 BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Models Mechan. 2015;8:237–251. doi:10.1242/dmm.017830.
   PubMed Web of Science ®Google Scholar
• Lomax ME, Barnes DM, Hupp TR, Picksley SM, Camplejohn RS. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene. 1998;17:643–649. doi:10.1038/sj.onc.1201974. PMID:9704930.
   PubMed Web of Science ®Google Scholar
• Lomax ME, Barnes DM, Gilchrist R, Picksley SM, Varley JM, Camplejohn RS. Two functional assays employed to detect an unusual mutation in the oligomerisation domain of p53 in a Li-Fraumeni like family. Oncogene. 1997;14:1869–1874. doi:10.1038/sj.onc.1201133. PMID:9150393.
   PubMed Web of Science ®Google Scholar
• Smardova J, Nemajerova A, Trbusek M, Vagunda V, Kovarik J. Rare somatic p53 mutation identified in breast cancer: a case report. Tumour Biol. 2001;22:59–66 doi:10.1159/000050597. PMID:11125276.
   PubMedGoogle Scholar
• Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013;73:3470–3480. doi:10.1158/0008-5472.CAN-12-4524-T. PMID:23633491.
   PubMed Web of Science ®Google Scholar
• Rao T, Ranger JJ, Smith HW, Lam SH, Chodosh L, Muller WJ. Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression. Breast Cancer Res. 2014;16:R11. doi:10.1186/bcr3603. PMID:24457046
   PubMed Web of Science ®Google Scholar
• Carlson CS, Emerson RO, Sherwood AM, Desmarais C, Chung MW, Parsons JM, Steen MS, LaMadrid-Herrmannsfeldt MA, Williamson DW, Livingston RJ, et al. Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun. 2013;4:2680. doi:10.1038/ncomms3680. PMID:24157944.
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-CTLA-4 antibodies of IgG2 a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2013;1:32–42. doi:10.1158/2326-6066.CIR-13-0013. PMID:24777248.
   PubMed Web of Science ®Google Scholar
• Fossati-Jimack L, Ioan-Facsinay A, Reininger L, Chicheportiche Y, Watanabe N, Saito T, Hofhuis FM, Gessner JE, Schiller C, Schmidt RE, et al. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fc gamma receptor III. J Exp Med. 2000;191:1293–1302. doi:10.1084/jem.191.8.1293.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fc gamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006;203:743–753. doi:10.1084/jem.20052283. PMID:16520392.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Bruhns P, Horiuchi K, Ravetch JV. Fc gamma RIV: A novel FcR with distinct IgG subclass specificity. Immunity. 2005;23:41–51. doi:10.1016/j.immuni.2005.05.010.
   PubMed Web of Science ®Google Scholar
• Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA, Wilson NS, Dranoff G, Brogdon JL. Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013;210:1685–1693. doi:10.1084/jem.20130573. PMID:23897982.
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok JD, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma. J Exp Med. 2013;210:1695–1710. doi:10.1084/jem.20130579. PMID:23897981.
   PubMed Web of Science ®Google Scholar
• Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ, Sharpe AH. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214:895–904. doi:10.1084/jem.20160801. PMID:28302645.
   PubMed Web of Science ®Google Scholar
• Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, et al. Tumor-Intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76:6964–6974. doi:10.1158/0008-5472.CAN-16-0258. PMID:27671674.
   PubMed Web of Science ®Google Scholar
• Gupta HB, Clark CA, Yuan B, Sareddy G, Pandeswara S, Padron AS, Hurez V, Conejo-Garcia J, Vadlamudi R, Li R, et al. Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer. Signal Transduction Targeted Therapy. 2016;1:16030. doi:10.1038/sigtrans.2016.30. PMID:28798885
   PubMed Web of Science ®Google Scholar
• Kaehler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Der Deutschen Dermatologischen Gesellschaft. 2011;9:277–285. doi:10.1111/j.1610-0387.2010.07568.x.
   PubMed Web of Science ®Google Scholar
• Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. Bmc Med. 2015;13:211. doi:10.1186/s12916-015-0455-8. PMID:26337719
   PubMed Web of Science ®Google Scholar
• Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A. 2015;112:6140–6145. doi:10.1073/pnas.1417320112. PMID:25918390.
   PubMed Web of Science ®Google Scholar
• Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162:1242–1256. doi:10.1016/j.cell.2015.08.052. PMID:26359984.
   PubMed Web of Science ®Google Scholar
• Cho HY, Choi EK, Lee SW, Jung KO, Seo SK, Choi IW, Park SG, Choi I, Lee SW Programmed death-1 receptor negatively regulates LPS-mediated IL-12 production and differentiation of murine macrophage RAW264.7 cells. Immunol Letters. 2009;127:39–47. doi:10.1016/j.imlet.2009.08.011.
   PubMed Web of Science ®Google Scholar
• Said EA, Dupuy FP, Trautmann L, Zhang Y, Shi Y, El-Far M, Hill BJ, Noto A, Ancuta P, Peretz Y, et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4(+) T cell activation during HIV infection. Nat Med. 2010;16:452–U136. doi:10.1038/nm.2106. PMID:20208540.
   PubMed Web of Science ®Google Scholar
• Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495–499. doi:10.1038/nature22396. PMID:28514441.
   PubMed Web of Science ®Google Scholar
• Lim TS, Chew V, Sieow JL, Goh S, Yeong JP, Soon AL, Ricciardi-Castagnoli P. PD-1 expression on dendritic cells suppresses CD8(+) T cell function and antitumor immunity. Oncoimmunology. 2016;5:e1085146. doi:10.1080/2162402X.2015.1085146. PMID:27141339.
   PubMed Web of Science ®Google Scholar
• Yao S, Wang S, Zhu Y, Luo L, Zhu G, Flies S, Xu H, Ruff W, Broadwater M, Choi IH, et al. PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood. 2009;113:5811–5818. doi:10.1182/blood-2009-02-203141. PMID:19339692.
   PubMed Web of Science ®Google Scholar
• Twyman-Saint\sVictor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373–377. doi:10.1038/nature14292. PMID:25754329.
   PubMed Web of Science ®Google Scholar
• Robert L, Harview C, Emerson R, Wang X, Mok S, Homet B, Comin-Anduix B, Koya RC, Robins H, Tumeh PC, et al. Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes. Oncoimmunology. 2014;3:2. doi:10.4161/onci.29244.
   Web of Science ®Google Scholar
• Robert L, Tsoi J, Wang X, Emerson R, Homet B, Chodon T, Mok S, Huang RR, Cochran AJ, Comin-Anduix B, et al. CTLA4 blockade Broadens the peripheral T-cell receptor repertoire. Clinical Cancer Res. 2014;20:2424–2432. doi:10.1158/1078-0432.CCR-13-2648.
   PubMed Web of Science ®Google Scholar
• Page DB, Diab A, Yuan J, Dong Z, Soloman SB, Patil S, Hudis CA, Wolchok JD, Norton L, McArthur HL Pre-operative immunotherapy with tumor cryoablation (cryo) plus ipilimumab (ipi) induces potentially favorable systemic and intratumoral immune effects in early stage breast cancer (ESBC) patients. 2015;3:O6. doi:10.1186/2051-1426-3-s1-06 PMCID: PMC4547170.
   Google Scholar
• Page DB, Yuan J, Redmond D, Wen YH, Durack JC, Emerson R, Solomon S, Dong Z, Wong P, Comstock C, et al. Deep Sequencing of T-Cell Receptor DNA as a biomarker of clonally expanded TILs in breast cancer after immunotherapy. Cancer Immunol Res. 2016;4(10):835–844. doi:10.1158/2326-6066.CIR-16-0013. PMID:27587469.
   PubMed Web of Science ®Google Scholar
• Noguchi T, Ward JP, Gubin MM, Arthur CD, Lee SH, Hundal J, Selby MJ, Graziano RF, Mardis ER, Korman AJ, et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res. 2017;5:106 doi:10.1158/2326-6066.CIR-16-0391. PMID:28073774.
   PubMed Web of Science ®Google Scholar
• Spranger S, Luke JJ, Bao R, Zha Y, Hernandez KM, Li Y, Gajewski AP, Andrade J, Gajewski TF. Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma. Proc Natl Acad Sci. 2016;113:E7759–E7768. doi:10.1073/pnas.1609376113. PMID:27837020.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD. Pooled analysis of long-term survival data from phase II and phase III trials of Ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33:1889–U1848. doi:10.1200/JCO.2014.56.2736. PMID:25667295.
   PubMed Web of Science ®Google Scholar
• McNamara MJ, Hilgart-Martiszus I, Barragan Echenique DM, Linch SN, Kasiewicz MJ, Redmond WL. Interferon-gamma production by peripheral lymphocytes predicts survival of tumor-bearing mice receiving dual PD-1/CTLA-4 blockade. Cancer Immunol Res. 2016;4:650–657. doi:10.1158/2326-6066.CIR-16-0022. PMID:27262113.
   PubMed Web of Science ®Google Scholar
• Stevanović S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, et al. Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017;356:200. doi:10.1126/science.aak9510. PMID:28408606.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. N Eng J Med. 2015;372:2006–2017. doi:10.1056/NEJMoa1414428.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. Nivolumab plus Ipilimumab in Advanced Melanoma. N Eng J Med. 2013;369:122–133. doi:10.1056/NEJMoa1302369.
   PubMed Web of Science ®Google Scholar
• Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123;2625–2635. doi:10.1182/blood-2013-11-492231. PMID:24578504.
   PubMed Web of Science ®Google Scholar
• Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12:269–281. doi:10.1038/nri3191. PMID:22437939.
   PubMed Web of Science ®Google Scholar
• Sakamoto K, Schmidt JW, Wagner KU. Generation of a novel MMTV-tTA transgenic mouse strain for the targeted expression of genes in the embryonic and postnatal mammary gland. Plos One. 2012;7:e43778. doi:10.1371/journal.pone.0043778.
   Web of Science ®Google Scholar
• Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nature Methods 2014;11:783–784. doi:10.1038/nmeth.3047. PMID:25075903.
   PubMed Web of Science ®Google Scholar